Reportlinker Adds Global Organ Preservation Solutions Industry

NEW YORK, June 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Organ Preservation Solutions Industry

http://www.reportlinker.com/p0209264/Global-Organ-Preservation-Solutions-Industry.html

This report analyzes the worldwide markets for Organ Preservation Solutions in US$ Thousands. The report provides separate comprehensive analytics for the North America, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period of 2006 through 2015. The report profiles 18 companies including many key and niche players such as 21st Century Medicine, BioLife Solutions, Inc., BioTime, Inc., Claris Lifesciences Limited, CryoLife, Inc., Dr. Franz Kohler Chemie GmbH, Genzyme Corporation, Lifeline Scientific, Teva Pharmaceutical Industries Ltd., ToleroTech Technology, Inc., and Vitrolife AB. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ORGAN PRESERVATION SOLUTIONS MCP-6177

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Introduction II-1

Market Snapshots II-1

Current & Future Analysis II-1

Competitive Scenario II-1

Table 1: Global Organ Preservation Solutions Market (2007):

Percentage Breakdown of Dollar Sales for Viaspan, Custodiol®

HTK, and Others (includes corresponding Graph/Chart) II-2

Pricing II-2

Market Trends II-2

Preservation Solutions - A Key to Deceased Donor Transplants II-2

UW Solution - The Preferred Solution for Liver, Pancreatic

Small Bowel Preservation II-2

Custodiol HTK Solution Gaining Prominence II-3

Euro-Collins Extending Opportunities in the Kidney Segment II-3

Cardiac Preservation Scenario Remains Static II-3

Lungs Preservation in Search of Ideal Solution II-3

Scientists See Cryopreservation as a Potential Means for

Organ Preservation II-3

Hypothermic Machine Perfusion - More Ideal for Liver

Preservation II-4

Measures to Address Organ Shortage to Infuse Demand for

Preservation Solutions II-4

Living Donors on the Rise II-4

Graying Population and Chronic Diseases Surge Need for

Transplants II-4

Transplant Tourism - Creating Brighter Avenues II-5

Combined Organ Transplantation - Gaining Attention II-5

Cardiac Arrest Death Patients - The Untapped Potential Donors II-5

2. PRODUCT OVERVIEW II-6

Definition II-6

Elements of Organ Preservation Solutions II-6

Elements and Functions of Organ Preservation Solutions II-6

Technical Specifications of the Organ Preservation Solutions II-6

Solutions in Concentrated Form II-7

Steps in Organ Preservation II-7

Identification of the Donor II-7

Organ Removal II-7

Organ Recovery and Preservation II-7

Organ Preservation Techniques II-8

Hypothermia II-8

Simple Cold Storage II-8

Continuous Hypothermic Perfusion II-8

Requirements of Ideal Preservation Solution II-8

Factors Determining Organ Viability II-9

Storage Duration Time II-9

Factors Impacting the Organ Preservation II-10

Hypothermia Induced Cell Swelling II-10

Cellular Acidosis and ATP Usage II-10

Compromised Membrane Function II-11

Functions of Organ Preservation Solutions II-11

Prevention of Reactive Oxygen Species Formation II-11

Reduction of Cell Swelling II-12

Prevention of Cellular Acidosis II-12

Benefits with Colloids II-13

Secondary Functions II-13

Production and Packaging II-14

Production II-14

Packaging II-14

Tests for Organ Preservation Solutions II-14

Hydroxymethylfurfural Test II-14

Particulate Contamination II-14

Test for Pyrogens II-14

Static Cold Storage - The Most Applied and Popular Technique II-15

Vitrification - A Promising Cryopreservation Approach for

Whole Organs II-15

Select Products II-15

Viaspan II-15

Composition of Viaspan II-16

Advantages II-16

Disadvantages II-16

Histidine-Tryptophan-Ketoglutarate (HTK) Solution -

Custodiol® HTK Solution II-17

Composition of Custodial HTK Solution II-17

Advantages II-17

Disadvantages II-17

Major Clinical Differences Between Custodiol HTK and Viaspan II-18

Collins Solution II-18

Euro Collins Solution II-18

Composition of Euro-Collins Solution II-18

Celsior Solution II-19

Composition of Celsior Solution II-19

Hypothermosol II-19

Perfadex® II-19

Advantages II-20

Ross-Marshall Citrate Solutions II-20

Phosphate-Buffered Sucrose Solution II-20

Lifor II-20

IGL-1 II-20

HBS Solution II-21

ET-Kyoto II-21

Composition of ET-Kyoto Solution II-21

Polysol II-21

TranSend II-21

siRNA Transplant Solutions II-22

HetaFreeze II-22

Background II-22

3. ORGAN TRANSPLANTATION II-23

Prelude II-23

Heart Transplantation II-23

Heart Diseases and Disorders II-23

Post Operative Complications and Consequences of Heart

Transplants II-24

Kidney Transplantation II-24

Kidney Disorders and Diseases II-24

Donor Evaluation II-25

Waiting List II-25

Surgery/Post-Operation II-25

Post-Operative Supervision and Issues II-25

Liver Transplantation II-25

Liver Disorders and Diseases II-26

Pancreas Transplantation II-26

Post Operative Complications and Consequences of Pancreas

Transplants II-27

Small Intestine Transplantation II-28

Intestine Disorders and Diseases II-28

Heart-and-Lung Transplantation II-28

Lung Transplantation II-28

Lung Diseases and Disorders II-29

Lung Patients Survival Statistics II-29

Transplantation Immunology II-29

Acute Cellular Rejection II-29

Chronic Rejection II-30

Post Transplant Observations II-30

Types of Donors II-30

Alive Donors II-30

Related Donors II-30

Good Samaritans II-31

Rewarded/Forced Donors II-31

Deceased Donors II-31

Directed / Allocated II-31

Organs Transplanted by Type of Donor II-31

Organ Donation and Eligibility Criteria II-32

Factors Considered for Matching Recipients to Donor Organs II-32

Testing II-32

Blood Typing II-32

Tissue Typing II-33

Issues Impacting Transplantation Market II-33

Scarcity of Donor Organs II-33

Organ Rejection II-33

Other Issues II-33

Ethical Concerns and Bioethical Issues II-34

Lack of Requisite Expertise II-34

Transplantation - Safety Requirements II-34

Waiting List II-35

Active Waiting List Patients II-35

Inactive Waiting List Patients II-35

Transplantation Expenses II-35

Major Medical and Non-Medical Expenses II-35

Major Milestones in Organ Transplantation II-36

4. RECENT INDUSTRY ACTIVITY II-37

Madrid's Puerta de Hierro Hospital Becomes the First User of

STEEN Solution™ Method II-37

Human BioSystems and San West Reverse Merge II-37

Lifeblood Medical Files a Drug Master File for Lifor® ACF

Perfusion Media II-37

BioLife Solutions Inks Distribution Agreement with Sigma-Aldrich II-38

Scottish Scientists Develop a Unique Preservative Solution II-38

CryoLife Enters into License Agreement with Trophic Solutions II-38

Vitrolife Performs First Lung Transplantations in North

America with STEEN Solution™ Technology II-39

Vitrolife Australian Approval for STEEN Solution™ II-39

5. FOCUS ON SELECT PLAYERS II-40

21st Century Medicine (US) II-40

BioLife Solutions, Inc. (US) II-40

BioTime, Inc. (US) II-40

Claris Lifesciences Limited (India) II-41

CryoLife, Inc. (US) II-41

Dr. Franz Kohler Chemie GmbH (Germany) II-42

Genzyme Corporation (US) II-42

Lifeline Scientific (US) II-42

Teva Pharmaceutical Industries Ltd. (Israel) II-42

ToleroTech Technology, Inc. (Canada) II-43

Vitrolife AB (Sweden) II-43

6. GLOBAL MARKET PERSPECTIVE II-44

Table 2: World Recent Past, Current & Future Analysis for

Organ Preservation Solutions by Geographic Region - North

America, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Thousand for Years

2006 through 2015 (includes corresponding Graph/Chart) II-44

Table 3: World 10-Year Perspective for Organ Preservation

Solutions by Geographic Region - Percentage Breakdown of

Dollar Sales for North America, Europe, and Rest of World

Markets for Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-45

III. MARKET

1. NORTH AMERICA III-1

A.Market Analysis III-1

Current & Future Analysis III-1

Organ Transplantation Scenario III-1

United States III-1

Number of Organ Transplants Witnesses Surge III-1

Statistical Overview III-2

Organ Transplants III-2

Table 4: US Organ Transplants (2006 & 2007): Number of

Transplants by Organ Type - Kidney, Liver, Heart, Lung,

Kidney-Pancreas, Multi-Organ, Pancreas After Kidney,

Pancreas Transplant Alone, Intestine, and Heart-Lung

(includes corresponding Graph/Chart) III-2

Living Donor Transplants III-3

Table 5: US Organ Transplants (2006 & 2007): Number of

Living Donor Transplants by Organ Type - Kidney, Liver,

Lung, Multi-Organ, Intestine, Heart, and Kidney-Pancreas III-3

Deceased Donor Transplants III-4

Table 6: US Organ Transplants (2006 & 2007): Number of

Deceased Donor Transplants by Organ Type - Kidney,

Liver, Heart, Lung, Kidney-Pancreas, Multi-Organ,

Pancreas After Kidney, Pancreas Transplant Alone,

Intestine, and Heart-Lung (includes corresponding

Graph/Chart) III-4

Organ Donors III-5

Table 7: US Organ Donors (2006 & 2007): Number of Donors

by Organ Type - Kidney, Liver, Heart, Pancreas, Lung,

Donation After Cardiac Death, and Intestine (includes

corresponding Graph/Chart) III-5

Living Donors III-5

Table 8: US Organ Donors (2006 & 2007): Number of Living

Donors by Organ Type - Kidney, Liver, Lung, Intestine,

Pancreas, and Heart III-5

Deceased Donors III-6

Table 9: US Organ Donors (2006 & 2007): Number of

Deceased Donors by Organ Type - Kidney, Liver, Heart,

Pancreas, Lung, Donation After Cardiac Death, and

Intestine (includes corresponding Graph/Chart) III-6

Waiting Lists III-7

Table 10: US Waiting List (2007): Total Patients by

Organ Type - Kidney, Liver, Heart, Kidney-Pancreas,

Lung, Pancreas After Kidney, Pancreas Transplant Alone,

Intestine, and Heart-Lung (includes corresponding

Graph/Chart) III-7

Patient Survival Rate III-8

Table 11: Patient Survival Percent by Organ Type for

1-Year and 5-Years (includes corresponding Graph/Chart) III-8

Table 12: Graft Survival Percent by Organ Type for

1-Year and 5-Years (includes corresponding Graph/Chart) III-9

Canada III-9

Canadians More Receptive to Organ Transplants III-9

Waiting List III-10

Success Rate of Organ Transplants III-10

Table 13: Success Rate of Organ Transplants After 1-Year

(includes corresponding Graph/Chart) III-10

Strategic Corporate Developments III-10

Select Players III-12

21st Century Medicine (US) III-12

BioLife Solutions, Inc. (US) III-12

BioTime, Inc. (US) III-13

CryoLife, Inc. (US) III-13

Genzyme Corporation (US) III-13

Lifeline Scientific (US) III-14

ToleroTech Technology, Inc. (Canada) III-14

B.Market Analytics III-15

Table 14: North American Recent Past, Current & Future

Analysis for Organ Preservation Solutions Analyzed with

Annual Sales Figures in US$ Thousand for Years 2006 through

2015 (includes corresponding Graph/Chart) III-15

2. EUROPE III-16

A.Market Analysis III-16

Current & Future Analysis III-16

Organ Transplantation Scenario in Select Markets III-16

Italy III-16

Surge in Organ Transplants III-16

United Kingdom III-16

Statistical Overview III-16

Transplants III-16

Table 15: UK Transplants (2007 & 2008): Number of

Transplants by Organ Type -Kidney (Deceased Donor Kidney

and Living Donor Kidney), Kidney and Pancreas, Pancreas,

Heart, Lungs, Liver (Deceased Donor Liver and Living

Donor Liver), Kidney and Liver, Heart/Lung, Multi-Organ,

and Kidney and Heart (includes corresponding

Graph/Chart) III-17

Donors III-18

Table 16: UK Donors (2007 & 08): Number of Donors by

Donor Type - Deceased and Living III-18

Waiting Lists III-18

Table 17: UK Transplants (2007 & 2008): Number of

Patients in the Active List by Organ Type - Kidney,

Liver, Kidney and pancreas, Lung, Heart, Pancreas, Other

Multi-Organ, and Heart/Lung (includes corresponding

Graph/Chart) III-18

Russia III-18

Organ Transplantations Show a Downward Trend in Russia III-18

Turkey III-19

Akdeniz University - A World-Renowned Transplantation Center III-19

Strategic Corporate Developments III-19

Select Players III-20

Dr. Franz Kohler Chemie GmbH (Germany) III-20

Vitrolife AB (Sweden) III-20

B.Market Analytics III-21

Table 18: European Recent Past, Current & Future Analysis

for Organ Preservation Solutions Analyzed with Annual Sales

Figures in US$ Thousand for Years 2006 through 2015

(includes corresponding Graph/Chart) III-21

3. REST OF WORLD III-22

A.Market Analysis III-22

Current & Future Analysis III-22

Organ Transplantation Scenario in Select Markets III-22

Asia-Pacific III-22

Australia III-22

Australia Registers Highest Success Rate in Transplantation III-22

Kidney Transplantation Snapshots III-22

Organ Donor Register III-22

China III-23

Organ Transplantations in China III-23

Cost Effective Transplant Procedures Lure Foreign Patients III-23

India III-23

Overview of Renal Transplantation III-23

Transplantation Expenses in India III-23

Japan III-24

Statistical Overview III-24

Table 19: Japanese Organ Transplants (2008): Unmet

Demand for Transplants by Organ - Kidney, Liver,

Intestine, Lung, and Heart (includes corresponding

Graph/Chart) III-24

Table 20: Japanese Organ Transplants (2007): Number of

Transplants by Organ - Kidney, Liver, Lung, and Heart

(includes corresponding Graph/Chart) III-24

Singapore III-25

Awareness Programs to Increase Living Kidney Donations in

Singapore III-25

Taiwan III-25

Taiwan Competes with the US in Kidney and Liver

Transplant Survival Rates III-25

Latin America III-25

Brazil - A Major Transplant Market III-25

Middle East III-25

Kuwait - A Rapidly Emerging 'Third World' Country in Organ

Transplants III-25

Strategic Corporate Development III-26

Select Players III-26

Claris Lifesciences Limited (India) III-26

Teva Pharmaceutical Industries Ltd. (Israel) III-27

B.Market Analytics III-27

Table 21: Rest of World Recent Past, Current & Future

Analysis for Organ Preservation Solutions Analyzed with

Annual Sales Figures in US$ Thousand for Years 2006 through

2015 (includes corresponding Graph/Chart) III-27

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 18 (including Divisions/Subsidiaries - 19)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 12

Canada 1

Europe 4

France 2

Germany 1

Rest of Europe 1

Asia-Pacific (Excluding Japan) 1

Middle East 1

------------------------------------------

To order this report:

Blood Supply, Tissue Banking and Transplantation Industry: Global Organ Preservation Solutions Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo